Publications
Detailed Information
Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ock, Chan-Young | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Kim, Sehui | - |
dc.contributor.author | Lee, Ju-Seog | - |
dc.contributor.author | Kim, Miso | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Jeon, Yoon Kyung | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Chung, Doo Hyun | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.date.accessioned | 2020-04-27T11:15:20Z | - |
dc.date.available | 2020-04-27T11:15:20Z | - |
dc.date.created | 2018-08-29 | - |
dc.date.created | 2018-08-29 | - |
dc.date.issued | 2016-05 | - |
dc.identifier.citation | Clinical Cancer Research, Vol.22 No.9, pp.2261-2270 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.other | 48151 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165316 | - |
dc.description.abstract | Purpose: There is currently no reliable biomarker to predict who wou ld benefit from anti-PD-1/PD-L1 inhibitors. We comprehensively analyzed the immunogenomic properties in The Cancer Genome Atlas (TCGA) according to the classification of tumor into four groups based on PD-L1 status and tumor-infiltrating lymphocyte recruitment (TIL), a combination that has been suggested tobe a theoretically reliable biomarker of anti-PD-1/PD-L1 inhibitors. Experimental Design: The RNA expression levels of PD-L1 and CD8A in the samples in the pan-cancer database of TCGA (N = 9,677) were analyzed. Based on their median values, the samples were classified into four tumor microenvironment immune types (TMIT). The mutational profiles, PD-L1 amplification, and viral association of the samples were compared according to the four TMITs. Results: The proportions of TMIT I, defined by high PD-L1 and CD8A expression, were high in lung adenocarcinoma (67.1%) and kidney clear cell carcinoma (64.8%) among solid cancers. The number of somatic mutations and the proportion of microsatellite instable-high tumor in TMIT I were significantly higher than those in other TMITs, respectively (P < 0.001). PD-L1 amplification and oncogenic virus infection were significantly associated with TMIT I, respectively (P < 0.001). A multivariate analysis confirmed that the number of somatic mutations, PD-L1 amplification, and Epstein-Barr virus/human papillomavirus infection were independently associated with TMIT I. Conclusions: TMIT I is associated with a high mutational burden, PD-L1 amplification, and oncogenic viral infection. This integrative analysis highlights the importance of the assessment of both PD-L1 expression and TIL recruitment to predict responders to immune checkpoint inhibitors. (C) 2016 AACR. | - |
dc.language | 영어 | - |
dc.publisher | American Association for Cancer Research | - |
dc.title | Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.contributor.AlternativeAuthor | 전윤경 | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 정두현 | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-15-2834 | - |
dc.citation.journaltitle | Clinical Cancer Research | - |
dc.identifier.wosid | 000375329100022 | - |
dc.identifier.scopusid | 2-s2.0-84968627725 | - |
dc.citation.endpage | 2270 | - |
dc.citation.number | 9 | - |
dc.citation.startpage | 2261 | - |
dc.citation.volume | 22 | - |
dc.identifier.sci | 000375329100022 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Jeon, Yoon Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Chung, Doo Hyun | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | BLOCKADE | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | RESPONSES | - |
dc.subject.keywordPlus | PEMBROLIZUMAB | - |
dc.subject.keywordPlus | NEOANTIGENS | - |
dc.subject.keywordPlus | LANDSCAPE | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.